CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition. Biochemical, biophysical and X-ray crystallography studies show that the membrane-distal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membrane-distal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interaction between TIM-3 and its four ligands (galectin 9, high mobility group protein B1, phosphatidyl serine, and carcinoembryonic antigen cell adhesion molecule 1) can diminish anti-tumor immunity through a variety of mechanisms including inducing CD8+ T cell death and exhaustion (Huang et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Huang et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We stimulated primary microglia with galectin-9 and CEACAM1, both of which mediate TIM-3 function in T cells by phosphorylating Y256 and Y263 residues34,35. This treatment had no effect on pSMAD2 expression”
From Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease (2025) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · cited 2×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 4×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
InfluentialHaploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Multiple Sequence Alignment Using ClustalW and ClustalX
Thompson, J. D., Gibson, T. J., & Higgins, D. G. (2003) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi0203s00 · Cited by 2,971 · cited 1×
“In addition, multiple sequencealignmentswereperformedusingClustalW 45 .”
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. W. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910048675 · Cited by 2,860 · cited 2×
“ThedatawereprocessedwithMosflm 40 andthe CCP 4softwaresuite 41 .”
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419
Cited by
Items 301–400 of 718
Polymorphisms in TIM-3 and breast cancer susceptibility in Chinese women: A case-control study
Wang, Z., Liu, X., Wang, X.-J., Chong, T., Lin, S., Wang, M., Ma, X., Liu, K., Xu, P., Feng, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9665 · Cited by 24
“Carcinoembryonic antigen cell adhesion molecule 1, another well-known molecule negatively regulating cellular activation, is co-expressed and forms a heterodimer with TIM-3 to regulate TIM-3-mediated tolerance and exhaustion [32, 33].”
BackgroundTumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer
Xiong, D., Wang, Y., & You, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-47382-3 · Cited by 33
Armitage, J. D., Newnes, H. V., McDonnell, A. M., Bosco, A., & Waithman, J. C. (2021) · Cells · doi:10.3390/cells10010056 · Cited by 28
Immune checkpoint blockade in hematological malignancies: current state and future potential
Pophali, P. A., Varela, J. C., & Rosenblatt, J. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1323914 · Cited by 29
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
Yang, Y. P., Yao, X., Wang, Q., Yang, M., Li, R., Qin, J., Zhuang, J., & Sun, C. (2026) · Advanced Science · doi:10.1002/advs.202520634 · Cited by 35
Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors
Ogawa, S., & Abe, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_4 · Cited by 23
Lake, C. M., Voss, K., Bauman, B. M., Pohida, K., Jiang, T., Dveksler, G. S., & Snow, A. L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03689-6 · Cited by 26
“Although other studies have suggested that TIM-3 and CEACAM1 do not interact(54), our study bolsters the argument that CEACAM1 plays a central role in TIM-3 regulation in CD8 effector T cells, consistent with the original interaction characterized by Huang et al.(38).”
ResultCheckpoints and immunity in cancers: Role of GNG12
Alausa, A. O., Victor, U. C., Fadahunsi, O. S., Owolabi, N., Adeniji, A., Olatinwo, M., Ogunlana, A. T., Olaleke, B., Balogun, T. A., Ogundepo, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106242 · Cited by 25
Blaeschke, F., Ortner, E., Stenger, D., Mahdawi, J., Apfelbeck, A., Habjan, N., Weißer, T., Kaeuferle, T., Willier, S. M., Kobold, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845499 · Cited by 26
Javid, H., Attarian, F., Saadatmand, T., Rezagholinejad, N., Mehri, A., Amiri, H., & Karimi‐Shahri, M. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30402 · Cited by 23
Pan, M., Zhao, H., Jin, R., Leung, P. S. C., & Shuai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156212 · Cited by 25
Translational Implication of Galectin-9 in the Pathogenesis and Treatment of Viral Infection
Lai, J., Luo, S., Wang, M., & Ho, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102108 · Cited by 27
“Tim-3 binds to carcinoembryonic antigen-related cell adhesion molecule 1 to induce T cell tolerance and exhaustion [34].”
BackgroundAlternative Checkpoints as Targets for Immunotherapy
Pant, A., Medikonda, R. T., & Lim, M. K. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00983-y · Cited by 25
Feng, C., Cao, L., Song, H., Xu, P., Chen, H., Xu, J., Zhu, X., Zhang, X., & Wang, X. (2015) · Viral Immunology · doi:10.1089/vim.2015.0062 · Cited by 25
Qiu, H., Shao, Z., Wen, X., Qu, D., Liu, Z., Chen, Z., Zhang, X., Ding, X., & Zhang, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05489-w · Cited by 25
Gutierrez, M. E., Tang, S., Powderly, J. D., Balmanoukian, A. S., Hoyle, P., Dong, Z., Cheng, L. L., Gong, X., Janik, J. E., Bourayou, N., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf144 · Cited by 27
“18,27,28 Binding of TIM-3 to PtdSer enables recognition and clearance of apoptotic cells, NF-κβ signaling, and interleukin-2 (IL-2) secretion, 18,29,30 and binding to HMGB-1 contributes to inhibition of innate immune response activation by impairing HMGB-1-mediated toll-like receptor signaling.”
Horlad, H., Ohnishi, K., Ma, C., Fujiwara, Y., Niino, D., Ohshima, K., Jinushi, M., Matsuoka, M., Takeya, M., & Komohara, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4774 · Cited by 25
“Recently, Huang et al demonstrated that carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) mediates TIM-3 activation and that blocking of the two molecules was required to induce lymphocyte activation (17).”
KIF18B is a Prognostic Biomarker and Correlates with Immune Infiltrates in Pan-Cancer
Qiu, M.-J., Wang, Q., Li, Q., Zhu, L., Li, Y., Yang, S., & Xiong, Z.-F. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.559800 · Cited by 24
“HAVCR2 (Tim-3), a crucial surface protein on exhausted T cells and anti-Tim-3 antibodies can affect the phenotype of myeloid cells in the TME (Huang et al., 2015).”
BackgroundInfluentialImmune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy
Jacquelot, N., Ghaedi, M., Warner, K., Chung, D. C., Crome, S. Q., & Ohashi, P. S. (2021) · Cancers · doi:10.3390/cancers13235967 · Cited by 23
Sun, T., Liu, S., Yang, G., Zhu, R., Li, Z., Yao, G., Chen, H., & Sun, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109152 · Cited by 25
Dumolard, L., Aspord, C., Marche, P. N., & Jílková, Z. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148111 · Cited by 28
T Cell CEACAM1–TIM-3 Crosstalk Alleviates Liver Transplant Injury in Mice and Humans
Kojima, H., Kadono, K., Hirao, H., Dery, K. J., Torgerson, T., Yao, S., Kaldas, F. M., Farmer, D. G., Blumberg, R. S., & Kupiec‐Weglinski, J. W. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.07.004 · Cited by 22
Self-citationCMA1 is potent prognostic marker and associates with immune infiltration in gastric cancer
Shi, S., Ye, S., Mao, J., Ru, Y., Lu, Y., Wu, X., Xu, M., Zhu, T., Wang, Y., Chen, Y., et al. (2020) · Autoimmunity · doi:10.1080/08916934.2020.1735371 · Cited by 22
“For T cell exhaustion, TIM-3, which is an essential membrane protein located within exhausted T cells [37], is con-”
BackgroundApoptosis, a Metabolic “Head-to-Head” between Tumor and T Cells: Implications for Immunotherapy
Franzese, O., Ancona, P., Bianchi, N., & Aguiari, G. (2024) · Cells · doi:10.3390/cells13110924 · Cited by 28
“Carcinoem-bryonic antigen cell adhesion molecule 1 (CEACAM1) promotes TIM-3 expression in T cells [139], which paradoxically protects newly activated T cells from premature apoptosis during expansion but contributes to late-stage effector T-cell exhaustion [140].”
BackgroundTargeting NETosis: nature’s alarm system in cancer progression
Liang, Y., Wu, G., Tan, J., Xiao, X., Yang, L., & Saw, P. E. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.24 · Cited by 34
Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy
Yao, Z., Zeng, Y., Liu, C., Jin, H., Wang, H., Zhang, Y., Ding, C., Chen, G., & Wu, D. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03195-5 · Cited by 34
“By interacting with its heterophilic ligand Carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1), Tim-3 prevents the phosphorylation of TCR signaling modules within effector T cells, ultimately inhibiting T cell activation [197].”
BackgroundClinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis
Tang, X., Shi, A., Xiong, Y., Zheng, K., Liu, Y., Shi, X.-G., Jiang, T., & Zhao, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693321 · Cited by 32
“(55) suggested that TIM-3 could be considered to inhibit the development of type-I immunity and to induce peripheral immune tolerance.”
BackgroundNovel Roles of the Tim Family in Immune Regulation and Autoimmune Diseases
Liu, Y., Chen, H., Chen, Z., Qiu, J., Pang, H., & Zhou, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748787 · Cited by 31
Tardos, E. C., Baglioni, M. V., & Bekiaris, V. (2021) · Cancers · doi:10.3390/cancers13184647 · Cited by 20
Yan, Q., Wang, M., Xia, H., Dai, C., Diao, T., Wang, Y., Hou, H., Zhang, H., Liu, M., & Long, X. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1084 · Cited by 27
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 24
The role of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer
Götz, L., Rueckschloss, U., Balk, G., Pfeiffer, V., Ergün, S., & Kleefeldt, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295232 · Cited by 22
D’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 23
Liu, H., Zhi, L., Duan, N., & Su, P. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12079 · Cited by 23
Li, Z., Lu, D., Yang, H., Li, Z., Zhu, P., Xie, J., Liao, D., Zheng, Y., & Li, H. (2021) · Veterinary Microbiology · doi:10.1016/j.vetmic.2021.108986 · Cited by 22
Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity
Dou, S., Li, G., Li, G., Hou, C., Zheng, Y., Tang, L., Gao, Y., Mo, R., Li, Y., Wang, R., et al. (2021) · eLife · doi:10.7554/elife.66501 · Cited by 25
“Estab-lishment of Tim-3 as an exhaustion marker in immune cells of both tumors and infectious diseases makes Tim-3 an attractive target for immunotherapy similar to PD-1 ( Huang et al., 2015 ), CTLA-4 ( Stamper et al., 2001 ), and Siglec-G ( Rangachari et al., 2012 ).”
InfluentialNovel immune targets for the treatment of triple-negative breast cancer
Corti, C., Nicolò, E., & Curigliano, G. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2006187 · Cited by 21
Krzyżanowska, N., Wojas‐Krawczyk, K., Milanowski, J., & Krawczyk, P. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063087 · Cited by 20
Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma
Astore, S., Baciarello, G., Cerbone, L., & Calabrò, F. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.33 · Cited by 29
Immunological and clinical implications of immune checkpoint blockade in human cancer
Kim, H., & Park, S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01140-1 · Cited by 22
Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors
Davar, D., & Zarour, H. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_2 · Cited by 22
CEACAM1 mediates B cell aggregation in central nervous system autoimmunity
Rovituso, D. M., Scheffler, L., Wunsch, M., Kleinschnitz, C., Doerck, S., Ulzheimer, J. C., Bayas, A., Steinman, L., Ergün, S., & Küerten, S. (2016) · Scientific Reports · doi:10.1038/srep29847 · Cited by 26
Chen, Y., Wang, P., Hu, Y., Yuan, Y., Yang, Y., Shi, H., Hao, Q., Lin, Z., Tian, J., Zheng, Y., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02805-5 · Cited by 22
New insight in immunotherapy and combine therapy in colorectal cancer
Ji, K., Jia, H., Liu, Z., Yu, G., Wen, R., Zhang, T., Peng, Z., Man, W., Tian, Y., Wang, C., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1453630 · Cited by 24
Zöller, J., Ebel, J., Khairnar, V., Schmitt, V., Klopfleisch, R., Meiners, J., Seiffart, V., Hansen, W., Buer, J., Singer, B. B., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1775464 · Cited by 18
“CEACAM1 deficiency inhibits the expression of inhibitory receptors CEACAM1 was described previously as an activation-induced inhibitory molecule on T cells similar to PD-1 and CTLA-4.”
InfluentialSaleh, R., Toor, S. M., & Elkord, E. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1841750 · Cited by 20
Liu, J., Chen, C., Geng, R., Shao, F., Yang, S., Zhong, Z., Ni, S., & Bai, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.09.037 · Cited by 21
“HAVCR2 is a key checkpoint molecule that regulates the inflammatory response which can induce T cell failure [59,60].”
BackgroundIdentification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy
Wu, M., Wu, A., Zhang, X., Li, Y., Li, B., Jin, S., Dong, Q., Niu, X., Zhang, L., Zhou, X., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115583 · Cited by 20
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 24
“Murine models revealed that the co-blockade of TIM3 and its ligand (CEACAM1) leads to enhanced antitumor immune responses, improving CRC clearance [127].”
BackgroundFlies, A. S., Blackburn, N. B., Lyons, A. B., Hayball, J. D., & Woods, G. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00513 · Cited by 19
“The cis heterodimerization is critical for stable surface expression of TIM-3 and its inhibitory function (172, 173).”
BackgroundAssessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma
Tam, K., Schoppy, D. W., Shin, J. H., Tay, J. K., Moreno‐Nieves, U. Y., Mundy, D. C., & Sunwoo, J. B. (2018) · Otolaryngology · doi:10.1177/0194599818756627 · Cited by 19
“Tumor-derived CEACAM1 also interacts with Tim-3 on T cells through their respective Nterminal domains, resulting in T-cell inhibition and exhaustion.(16) We demonstrate that NK cell immune pressure upregulates CEACAM1 on HNSCC tumor cells as well as primary human NK cells (Figure 1).”
BackgroundBurman, S. S. R., Nance, M. L., Jeliazkov, J. R., Labonte, J. W., Lubin, J. H., Biswas, N., & Gray, J. J. (2019) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25855 · Cited by 21
Martín, P., Blanco-Domínguez, R., & Sánchez‐Díaz, R. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00586-4 · Cited by 18
“Galectin-9, the first reported Tim-3 ligand, was shown to induce apoptosis in Th1 cells,(13) and carcinoembryonic antigen cell adhesion molecule 1 forms a heterodimer with Tim-3 to mediate T cell inhibition and exhaustion.(14) TIGIT is a coinhibitory transmembrane protein expressed by regulatory and memory CD4 T cells…”
BackgroundImmune checkpoint blockade for cancer therapy: current progress and perspectives
Ye, H., Liao, W., Pan, J., Shi, Y. P., & Wang, Q. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2300492 · Cited by 27
“It plays an inhibitory role through binding to different ligands, including galectin 9, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), phos ‐ phatidylserine (PS), and high-mobility group box 1 (HMGB1) (Zhu et al., 2005; Chiba et al., 2012; Huang et al., 2015).”
The role of A Disintegrin and Metalloproteinase (ADAM)-10 in T helper cell biology
Sezin, T., Selvakumar, B., & Scheffold, A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119192 · Cited by 19
Grottoli, M., Carrega, P., Zullo, L., Dellepiane, C., Rossi, G., Parisi, F., Barletta, G., Zinoli, L., Coco, S., Alama, A., et al. (2022) · Cancers · doi:10.3390/cancers14205046 · Cited by 18
“Thus, while it has been reported that, to exert its function, TIM-3 should interact with Carcinoembryonic antigen related cell adhesion molecule (CEACAM)-1 (in cis and/or trans) [38], a recent study does not provide any evidence for an interaction between these receptors, suggesting that the inhibitory signaling in ef…”
BackgroundZhu, W., Tan, Y., & Wang, F. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109185 · Cited by 18
Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints
Dulal, D., Boring, A. R., Terrero, D., Johnson, T. L., Tiwari, A. K., & Raman, D. (2023) · Cancers · doi:10.3390/cancers15102774 · Cited by 23
Vilela, T., Valente, S., Correia, J., & Ferreira, F. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189144 · Cited by 21
Genome-Wide CRISPR Screen Identifies Host Factors Required by Toxoplasma gondii Infection
Wu, S.-Z., Wei, H.-X., Jiang, D., Li, S.-M., Zou, W., & Peng, H.-J. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00460 · Cited by 18
Liu, J., Mi, J., Liu, S., Chen, H., & Jiang, L. (2022) · FEBS Open Bio · doi:10.1002/2211-5463.13479 · Cited by 18
Yoshida, T., Nakamoto, T., Atsumi, N., Ohe, C., Sano, T., Yasukochi, Y., Tsuta, K., & Kinoshita, H. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009358 · Cited by 19
Wei, Q., & Taskén, K. (2022) · Biochemical Journal · doi:10.1042/bcj20210233 · Cited by 19
Huang, J., Zhou, L., & Deng, K. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01140-2 · Cited by 16
“Huang YH, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.”
BackgroundInfluentialPotts, M., Fletcher-Etherington, A., Nightingale, K., Mescia, F., Bergamaschi, L., Calero‐Nieto, F. J., Antrobus, R., Williamson, J. C., Parsons, H. T., Huttlin, E. L., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112613 · Cited by 21
Kou, L., Xie, X., Chen, X., Li, B., Li, J., & Li, Y. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03568-3 · Cited by 19
“In addition, on activated T cells, TIM-3 and carcinoembryonic antigen-related cell adhesion molecule 1 are co-expressed and form heterodimers, thereby suppressing T cell function and downregulating their antitumor immunity [49].”
BackgroundCo‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma
Lucca, L. E., & Hafler, D. A. (2017) · Immunological Reviews · doi:10.1111/imr.12529 · Cited by 18
Zhang, Y., Jiang, N., Zhang, T., Chen, R., Feng, Y., Sang, X., Yang, N., & Chen, Q. (2019) · Parasites & Vectors · doi:10.1186/s13071-019-3788-x · Cited by 18
Self-citationA novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
Kuang, Z., Li, L., Zhang, P., Chen, B., Wu, M., Ni, H., Yi, S., Zou, J., & Liu, J. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa022 · Cited by 22
“Although TIM-3 has multiple ligands, the crystal structure suggests that PtdSer, CEACAM1 and HMGB1 binding sites depend on hydrophobic residues in the FGCC’ loop [9–11].”
BackgroundInfluentialPerspectives on immune checkpoint ligands: expression, regulation, and clinical implications
Moon, J., Oh, Y. M., & Ha, S. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.8.054 · Cited by 18
“Although expression of Gal-9 (73-75) or CEACAM1 (72, 76-78) in tumor cells and/or immune cells has been addressed, the factors implicated in their regulation have not been well”
BackgroundInfluentialYun, S. J., Lee, B., Komori, K., Lee, M. J., Lee, B. G., Kim, K. H., & Park, S. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.12.006 · Cited by 20
Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
Sasikumar, P. G., & Ramachandra, M. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100073 · Cited by 17
Recent developments in peptide vaccines against Glioblastoma, a review and update
Salahlou, R., Farajnia, S., Alizadeh, E., & Dastmalchi, S. (2025) · Molecular Brain · doi:10.1186/s13041-025-01221-x · Cited by 21
“In contrast to PD-1, it functions during the later phases of T-cell dysfunction, positioning it as a viable target for combination therapies [36, 45].”
Jin, Y.-J., Yu, D., Tian, X., Li, H., Zhou, X.-C., Kong, Y., Zhang, W., Zhang, L., Cheng, L., Yang, Z., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00707-3 · Cited by 17
Datta, R. R., Schran, S., Persa, O.-D., Aguilar, C., Thelen, M., Lehmann, J., Garcia-Marquez, M. A., Wennhold, K., Preugszat, E., Zentis, P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3746 · Cited by 19
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
Inocencio, J. F., Mitrasinovic, S., Asad, M., Parney, I. F., Zang, X., & Himes, B. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424396 · Cited by 23
Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression
Luo, J., Zhang, C., Chen, D., Chang, T., Chen, S., Lin, Z., Yi, C., & Tang, Z. (2024) · European journal of medical research · doi:10.1186/s40001-024-02203-w · Cited by 20
Role of Tim-3 in regulating tumorigenesis, inflammation, and antitumor immunity therapy
Cao, Y., Li, Q., Liu, H., He, X., Huang, F., & Wang, Y. (2021) · Cancer Biomarkers · doi:10.3233/cbm-210114 · Cited by 15
“It is found to be expressed on T-cells and by way of the interaction of IgV domains on two molecules, binds to Tim-3 [28].”
Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies
Polania, J. W., Lerner, E., Wilkinson, D. S., Hoyt-Miggelbrink, A. M., & Fecci, P. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.777073 · Cited by 18
Peng, Q., Hao, L., Guo, Y., Zhang, Z., Ji, J.-M., Xue, Y., Liu, Y., Lu, J., Li, C.-G., & Shi, X. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i13.3989 · Cited by 20
Islam, M., Sevak, J. K., Kumar, M., Jindal, A., Vyas, A. K., Bajpai, M., Ramakrishna, G., Sarin, S. K., & Trehanpati, N. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17306 · Cited by 16
Immunoregulation effects of TIM-3 on tumors
Sheng, C. C., & Han, F. (2018) · Neoplasma · doi:10.4149/neo_2018_180610n385 · Cited by 17
Targeting novel inhibitory receptors in cancer immunotherapy
Ding, Q., Chauvin, J.-M., & Zarour, H. M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101436 · Cited by 18
“Sabatos-Peyton CA, Nevin J, Brock A, Venable JD, Tan DJ, Kassam N, Xu F, Taraszka J, Wesemann L, Pertel T, Acharya N, Klapholz M, Etminan Y, Jiang X, Huang YH, Blumberg RS, Kuchroo VK, Anderson AC, Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functi…”
BackgroundInfluentialImmunotherapeutic Approaches in Malignant Pleural Mesothelioma
Terenziani, R., Zoppi, S., Fumarola, C., Alfieri, R. R., & Bonelli, M. A. (2021) · Cancers · doi:10.3390/cancers13112793 · Cited by 18
“Ceacam1 is co-expressed with TIM-3 on T cells, acting as a negative regulator of T cells activities [63].”
BackgroundWeber, J. K., & Zhou, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-14064-x · Cited by 15
Structural basis of the dynamic human CEACAM1 monomer-dimer equilibrium
Gandhi, A. K., Sun, Z.-Y. J., Kim, W. M., Huang, Y., Kondo, Y., Bonsor, D. A., Sundberg, E. J., Wagner, G., Kuchroo, V. K., Petsko, G. A., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01871-2 · Cited by 16
Self-citationJacob, R. A., Edgar, C. R., Prévost, J., Trothen, S. M., Lurie, A., Mumby, M. J., Galbraith, A., Kirchhoff, F., Haeryfar, S. M. M., Finzi, A., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101042 · Cited by 16
Ma, L.-R., Li, J., Tang, L. L., Li, R., Yang, J., Sun, A., Leung, E. L., & Yan, P. (2021) · Oncology Letters · doi:10.3892/ol.2021.13048 · Cited by 21
Ueshima, C., Kataoka, T. R., Takei, Y., Hirata, M., Sugimoto, A., Hirokawa, M., Okayama, Y., Blumberg, R. S., & Haga, H. (2017) · Cancer Medicine · doi:10.1002/cam4.1050 · Cited by 14
“function of these cells via homophilic binding to CEACAM1 or heterophilic binding to T- cell immunoglobulin domain and mucin domain3 and NK gene complex group 2 member D (NKGD2), followed by the downregulation of antitumor immunity [4, 44].”
BackgroundSelf-citationWillison, A., Hagler, R., Weise, M., Elben, S., Huntemann, N., Masanneck, L., Pfeuffer, S., Lichtenberg, S., Golombeck, K. S., Preuth, L.-M., et al. (2025) · Cells · doi:10.3390/cells14070552 · Cited by 15
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
Li, Y., Kang, Z., & Du, Y. (2026) · Medicine Bulletin · doi:10.1002/mdb2.70018 · Cited by 22
Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy
Bautista, J., Echeverría, C. E., Maldonado-Noboa, I., Adatty-Molina, J., Urresta, S. S., Coral-Riofrio, E. C., Araujo‐Abad, S., Kyriakidis, N. C., & López-Cortés, A. (2026) · Journal of Immunology Research · doi:10.1155/jimr/7864229 · Cited by 16
An Emerging Role of TIM3 Expression on T Cells in Chronic Kidney Inflammation
Lu, C., Chen, H., Wang, C., Yang, F., Li, J., Liu, H., & Chen, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.798683 · Cited by 14
“A variety of ligands with different binding sites have been reported in association with TIM3 activation, including galectin 9 (GAL9) (63), carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) (64), phosphatidylserine (PtdSer) (65), and high mobility group protein B1 (HMGB1) (66).”
BackgroundThe landscape of immune dysregulation in pediatric sepsis at a single-cell resolution
Alhamdan, F., Koutsogiannaki, S., & Yuki, K. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110175 · Cited by 16
The role of TIM-3 in sepsis: a promising target for immunotherapy?
Wang, C., Liu, J., Wu, Q., Wang, Z., Hu, B., & Bo, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328667 · Cited by 16
“It interacts with four primary ligands: Gal-9 (22), CEACAM1 (23), HMGB1 (24), and PtdSer (25) (Figure 1).”
BackgroundInfluentialZhang, L., Xie, P., Li, M., Zhang, X., Fei, S., Zhao, N., Li, L., Xie, Q., Xu, Z., Tang, W., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001003 · Cited by 14
“[25,26] Interestingly, CEACAM1 is detected in the serum and bile of patients with obstructive jaundice, as well as a rat model of cholestatic liver injury induced by bile duct ligation (BDL).”
InfluentialWang, W., Xu, Z., Zhang, J., Wang, S., Ge, W., Li, X., Mou, W., Wang, X., Chai, W., Zhao, J., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108641 · Cited by 14
Zych, M., Roszczyk, A., Kniotek, M., Dabrowski, F. A., & Zagożdżon, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184182 · Cited by 14
“There are two main ligands for TIM-3: C-type lectin galectin-9 (Gal-9) and CEACAM1 protein [8,9].”
BackgroundPiancone, F., Saresella, M., Marventano, I., Rosa, F. L., Caputo, D., Mendozzi, L., Rovaris, M., & Clerici, M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801625 · Cited by 14
“Finally, Th1-polarized cells from mice with transgenic overexpression of TIM-3 that lacked CEACAM-1 (TIM-3Tg CEACAM-1) were shown to be resistant to Gal-9–induced apoptosis, a phenomenon that is mediated by Gal-9 binding to TIM-3 (20).”
BackgroundInfluentialMolecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor
Jiang, X., Li, L., Li, Y., & Li, Q. (2019) · Journal of Cancer · doi:10.7150/jca.26481 · Cited by 17
Metadata
- Authors
- Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., Clayton, K. L., Raab, M., Chen, Q., Beauchemin, N., Yazaki, P. J., Pyzik, M., Ostrowski, M. A., Glickman, J. N., Rudd, C. E., Ploegh, H. L., Franke, A., Petsko, G. A., Kuchroo, V. K., & Blumberg, R. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Brandeis University (US)
- Massachusetts Institute of Technology (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Oslo University Hospital (NO)
- University of Toronto (CA)
- University of Cambridge (GB)
- Sichuan University (CN)
- McGill University (CA)
- City Of Hope National Medical Center (US)
- St. Michael's Hospital (CA)
- Corresponding author
- Blumberg, Richard S.
- ORCID
- Venue
- Nature
- Published
- 2014-10-26
- Volume
- 517
- Issue
- 7534
- Pages
- 386-390
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4297519
- OpenAlex
- W2122730216
- Cited by
- 717
- References
- 58
- Citations by year
- 2026: 44 · 2025: 72 · 2024: 85 · 2023: 82 · 2022: 71 · 2021: 82 · 2020: 76 · 2019: 51 · 2018: 47 · 2017: 40 · 2016: 38 · 2015: 28
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001102)
- National Institute of General Medical Sciences (R01GM032415, T32GM007122, GM-32415, R37GM032415, P41GM111244, R01GM026788)
- National Institute of Allergy and Infectious Diseases (AI 056299, P01AI073748, AI039671, AI073748, P01AI056299, P01AI039671)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK044319, DK0034854, R01DK053056, DK088199, DK053056, R56DK053056, DK051362, R37DK044319, R01DK051362, P30DK034854, R01DK044319, R01DK088199)
- National Institute of Neurological Disorders and Stroke (NS045937, R01NS045937)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- TIM-3, T cell exhaustion, immune tolerance, immune checkpoint, T cell co-inhibition, T cell costimulation, colorectal cancer, antitumor immunity, T cell receptor signaling
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Cell Line, Disease Models, Animal, Female, Humans, Immune Tolerance, Inflammation, Ligands, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Models, Molecular, Mucous Membrane, Protein Conformation, Receptors, Virus, T-Lymphocytes, Colorectal Neoplasms, Autoimmunity, Antigens, CD, Cell Adhesion Molecules, Mice, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.